DiGeorge Syndrome (22q11.2 Deletion)
A chromosomal microdeletion syndrome affecting immune, cardiac, and endocrine development, ranging from mild learning and immune differences to severe combined immunodeficiency requiring specialized care.
- Multidisciplinary Specialist Access
- Immune Workup Review
- Cardiac & Endocrine Coordination
- Genetic Cause
- 22q11.2 Microdeletion
- Key Feature
- Thymic Hypoplasia/Aplasia
- Inheritance
- De Novo (90%) / Autosomal Dominant
- Advanced Therapies
- Thymus Transplant, T-cell Reconstitution
Condition Overview
DiGeorge syndrome, caused by a microdeletion on chromosome 22 (22q11.2), is one of the most common chromosomal deletion syndromes. It affects the development of several structures that arise from the same embryonic tissue, most notably the thymus, parathyroid glands, and the outflow tract of the heart.
Clinical presentation is highly variable. Some individuals have only mild learning differences or subtle facial features, while others โ particularly those with complete thymic aplasia โ present in infancy with severe combined immunodeficiency-like T-cell deficiency requiring urgent specialized care.
Because the syndrome affects multiple organ systems, coordinated care across immunology, cardiology, endocrinology, and developmental specialists is central to management, and outcomes have improved substantially with early recognition and access to thymic transplantation for the most severely affected infants.
Types and Variants
DiGeorge syndrome is classified by the degree of immune involvement, which drives the urgency and type of specialist management needed.
Symptoms and Signs
Features vary widely depending on which organ systems are most affected, and not every feature is present in every individual.
Causes and Risk Factors
DiGeorge syndrome results from a deletion of a segment of chromosome 22 affecting genes important for development of the pharyngeal arches during early pregnancy.
Diagnosis and Investigations
Diagnosis is confirmed by genetic testing for the 22q11.2 deletion, prompted by characteristic clinical features such as congenital heart disease, hypocalcemia, or immune deficiency.
Immune Severity Classification
Rather than formal staging, DiGeorge syndrome is classified by immune severity, which determines urgency of specialist management.
Standard Treatment Options
Management is multidisciplinary, addressing immune, cardiac, endocrine, and developmental needs in parallel, with the most urgent focus on infants with complete thymic aplasia.
Advanced and Emerging Treatment Options
The most advanced intervention in DiGeorge syndrome addresses the underlying absence of thymic tissue itself in the most severely affected infants.
Cellular/Tissue Therapy
Cultured thymus tissue implantation
Specialized transplantation of donor thymus tissue to restore T-cell development in infants with complete athymic DiGeorge syndrome.
Cellular Therapy
Hematopoietic stem cell transplant (select cases)
Considered in select complex presentations where thymus transplant is not feasible or available.
Immunoglobulin Support
Immunoglobulin replacement
Used as supportive therapy in patients with significant antibody deficiency overlap.
Precision Medicine
Genotype-phenotype correlation research
Ongoing work to better predict severity and complication risk from deletion size and specific gene involvement.
Biomarkers and Precision Medicine
Immune and endocrine markers guide both initial classification and ongoing monitoring of DiGeorge syndrome.
When a Second Opinion May Be Important
Given how many organ systems are involved, several scenarios benefit from specialist multidisciplinary re-evaluation.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Outcomes in DiGeorge syndrome depend heavily on the severity of immune and cardiac involvement; most individuals with partial disease have a good long-term outlook with coordinated care, while complete athymic disease requires urgent, specialized intervention but has seen meaningfully improved outcomes with thymus transplantation.
Supportive Care and Living With DiGeorge Syndrome
Supporting a child or adult with DiGeorge syndrome involves coordinated specialist follow-up alongside developmental, nutritional, and emotional support.
How CancerFax Helps You Explore Treatment Options
CancerFax can help coordinate review of genetic and immune workup results, facilitate second opinions on complex cardiac or immune presentations, and connect families with centers offering thymus transplantation and multidisciplinary 22q11.2 care.
Get a free case reviewFrequently Asked Questions
DiGeorge syndrome is a genetic condition caused by a deletion on chromosome 22 (22q11.2) that affects development of the thymus, parathyroid glands, heart, and other structures, producing a wide range of possible features.
Signs can include a congenital heart defect detected before or at birth, low calcium causing muscle twitching or seizures in infancy, feeding difficulties, or recurrent infections.
Yes โ it is caused by a microdeletion on chromosome 22q11.2, occurring as a new (de novo) deletion in about 90% of cases and inherited from a parent in about 10%.
Diagnosis is confirmed with genetic testing, typically FISH or chromosomal microarray, often prompted by congenital heart disease, hypocalcemia, or abnormal newborn immune screening.
It is the most severe form, in which the thymus fails to develop at all, leaving the infant with essentially no T-cell immunity, similar to severe combined immunodeficiency.
It is a specialized procedure using cultured donor thymus tissue to restore T-cell development in infants with complete athymic DiGeorge syndrome, available at a limited number of centers.
Yes โ many individuals have some degree of learning difference, speech delay, or increased risk of conditions such as anxiety, ADHD, or psychiatric illness later in life.
It is a lifelong genetic condition rather than one that is cured, though many features โ cardiac defects, low calcium, and even absent thymic function in some infants โ can be effectively treated or managed.
Both result from the same 22q11.2 deletion; velocardiofacial syndrome is often used when cleft palate, speech, and facial features are the predominant presenting features.
Yes. CancerFax can help coordinate review of genetic and immune test results, facilitate second opinions for complex cardiac or immune presentations, and connect families with specialist centers offering thymus transplantation and multidisciplinary 22q11.2 care.
Get Coordinated Specialist Care for DiGeorge Syndrome
Send genetic and immune workup results for specialist review and explore multidisciplinary treatment options.